A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
The end of the COVID-19 sales opportunity was clearly visible in Medtech Insight ’s latest annual listing of the top 100 global medtech players by revenues for 2023. Medtronic once again assumed prid
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
Volatile Reactions To Benign Results Johnson & Johnson (J&J) kicked off the third-quarter earnings season for the life sciences with a mixed but generally positive reception. The company’s st